-
Headache Jun 1997We conducted a pilot study of intravenous droperidol in 35 patients (32 women and 3 men; mean age 43 years) with status migrainosus (n = 25) or refractory migraine (n =...
We conducted a pilot study of intravenous droperidol in 35 patients (32 women and 3 men; mean age 43 years) with status migrainosus (n = 25) or refractory migraine (n = 10) in an ambulatory infusion center. Headache was graded as severe in 21 patients and moderate in 14. An intravenous line was started and kept open. Droperidol (2.5 mg) was given intravenously every 30 minutes until either three doses were given or the patient was completely or almost headache-free prior to the next dose. Seven patients received one dose, 12 received two doses, and 16, three doses (mean 5.6 mg). Our success rate (headache-free or mild headache) was 88% (22 of 25) in patients with status migrainosus and 100% (10 of 10) in patients with refractory migraine. The average time to headache improvement was 40 minutes (n = 35), to mild headache--60 minutes (n = 32), and to headache-free--105 minutes (n = 28). Nausea, vomiting, and light and sound sensitivity resolved in all but 5 patients. Four patients had an asymptomatic systolic blood pressure drop > or = 20 mm Hg. Most patients were sedated (34 of 35). Five patients developed akathisia and 1 dystonia. At follow-up 24 hours after discharge, the recurrence rate (headache intensity from none or mild to moderate or severe) was 23% in status migrainosus and 10% in refractory migraine. Twenty-one patients were sedated, while 19 had extrapyramidal symptoms, mainly restlessness. Droperidol is effective and safe in treating status migrainosus or refractory migraine. Hypotension was uncommon. Patients should be warned of sedation and akathisia.
Topics: Adolescent; Adult; Antiemetics; Antipsychotic Agents; Droperidol; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain, Intractable; Pilot Projects; Time Factors
PubMed: 9237411
DOI: 10.1046/j.1526-4610.1997.3706377.x -
CMAJ : Canadian Medical Association... Apr 2002
Topics: Canada; Cardiovascular Diseases; Death; Dopamine Antagonists; Droperidol; Electrocardiography; Female; Humans; Incidence; Male; Risk Assessment
PubMed: 11949994
DOI: No ID Found -
The Journal of Clinical Psychiatry Jul 1984In a double-blind clinical study, 27 acutely agitated patients were treated with an intramuscular injection of 5 mg of droperidol or 5 mg of haloperidol from identical... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
In a double-blind clinical study, 27 acutely agitated patients were treated with an intramuscular injection of 5 mg of droperidol or 5 mg of haloperidol from identical appearing vials. At 30 minutes following treatment, 81% of the patients treated with haloperidol but only 36% treated with droperidol required a second injection (p less than .05). Thus, droperidol, a safe butyrophenone neuroleptic, appears to be a drug of choice for rapid and reliable control of acute agitation.
Topics: Acute Disease; Adolescent; Adult; Aged; Clinical Trials as Topic; Commitment of Mentally Ill; Dangerous Behavior; Double-Blind Method; Droperidol; Emergency Services, Psychiatric; Haloperidol; Humans; Injections, Intramuscular; Middle Aged; Psychomotor Agitation; Psychotic Disorders; Random Allocation
PubMed: 6376480
DOI: No ID Found -
Anesthesia and Analgesia Nov 1994To further investigate possible prolongation of the frequency-corrected QT interval (QTc interval) after administration of droperidol (DRO), we studied 40 surgical... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
To further investigate possible prolongation of the frequency-corrected QT interval (QTc interval) after administration of droperidol (DRO), we studied 40 surgical patients who were randomly assigned to one of three groups, receiving an intravenous (IV) injection of either 0.1 mg/kg (Group 1, n = 10), 0.175 mg/kg (Group 2, n = 10), or 0.25 mg/kg (Group 3, n = 20) of DRO at induction of anesthesia. The QTc interval, heart rate, and arterial pressure were registered before and 1, 2, 3, 4, 5, 7.5, and 10 min after the respective dose injection. Significant prolongations of the median QTc interval were found in patients from all groups, ranging from 37 ms (8.0%) in Group 1, to 44 ms (10.6%) in Group 2, to 59 ms (14.9%) in Group 3, when compared with control. The heart rate showed a significant increase in all groups. Mean arterial pressure (MAP) was slightly but significantly decreased in Groups 1 and 3. Prolongation of the QTc interval is a predictable and dose-dependent side effect after injection of high-dose DRO.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Droperidol; Electrocardiography; Heart Rate; Humans; Prospective Studies
PubMed: 7978420
DOI: 10.1213/00000539-199411000-00028 -
European Journal of Hospital Pharmacy :... Mar 2020Nefopam has been reported to be effective in postoperative pain control with an opioid-sparing effect, but the use of nefopam can lead to nausea and vomiting. To prevent...
INTRODUCTION
Nefopam has been reported to be effective in postoperative pain control with an opioid-sparing effect, but the use of nefopam can lead to nausea and vomiting. To prevent these side effects, droperidol can be mixed with nefopam. In intensive care units, high concentrations of nefopam and droperidol in syringes can be used with a continuous flow.
OBJECTIVES
The first objective of this work was to study the physicochemical stability of a nefopam solution 2.5 mg/mL diluted in NaCl 0.9% in polypropylene syringes immediately after preparation and after 6, 24 and 48 hours at room temperature. The second objective was to study the physicochemical stability of mixtures of nefopam 2.5 mg/mL and droperidol 52 µg/mL diluted in NaCl 0.9% in polypropylene syringes at room temperature over 48 hours.
MATERIALS AND METHODS
Three syringes for each condition were prepared. For each time of analysis, three samples for each syringe were prepared and analysed by high performance liquid chromatography coupled to photodiode array detection. The method was validated according to the International Conference on Harmonisation Q2(R1). Physical stability was evaluated by visual and subvisual inspection (turbidimetry by UV spectrophotometry). pH values were measured at each time of analysis.
RESULTS
Solutions of nefopam at 2.5 mg/mL and the mixture of nefopam 2.5 mg/mL with droperidol 52 µg/mL, diluted in NaCl 0.9%, without protection from light, retained more than 90% of the initial concentration after 48 hours storage at 20-25°C. No modification in visual or subvisual evaluation and pH values were observed.
CONCLUSION
Nefopam solutions at 2.5 mg/mL and the mixture of nefopam 2.5 mg/mL with droperidol 52 µg/mL diluted in NaCl 0.9% were stable over a period of 48 hours at room temperature. These stability data provide additional knowledge to assist intensive care services in daily practice.
Topics: Chemical Phenomena; Chromatography, High Pressure Liquid; Droperidol; Humans; Intensive Care Units; Nefopam; Pharmaceutical Solutions; Polypropylenes; Syringes
PubMed: 32296509
DOI: 10.1136/ejhpharm-2019-001856 -
Annals of Emergency Medicine Apr 1992To compare two related pharmacological agents used for the chemical restraint of agitated and combative patients. (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
STUDY OBJECTIVE
To compare two related pharmacological agents used for the chemical restraint of agitated and combative patients.
DESIGN AND SETTING
A randomized, double-blind, prospective study was carried out in patients requiring physical restraint in a university hospital emergency department.
PARTICIPANTS
Sixty-eight violent or agitated adult patients whom the attending physician believed would benefit from chemical restraint to protect the patient and staff and to expedite evaluation.
INTERVENTION
Twenty-one participants were administered 5 mg haloperidol IM; 26 were administered 5 mg droperidol IM; 12 were administered haloperidol IV; and nine were administered 5 mg droperidol IV.
RESULTS
All patients were rated on a five-point combativeness scale at five, ten, 15, 30, and 60 minutes after the study drug was given. Vital signs also were recorded at these times. IM droperidol decreased combativeness significantly more than IM haloperidol at ten (P = .006), 15 (P = .01), and 30 (P = .04) minutes. There was no significant difference between the two drugs when given by the IV route (beta at the 5% confidence level, P = .78).
CONCLUSION
In equal IM doses (5 mg), droperidol results in more rapid control of agitated patients than haloperidol, without any increase in undesirable side effects.
Topics: Adult; Aggression; Blood Pressure; Double-Blind Method; Droperidol; Emergencies; Emergency Service, Hospital; Female; Haloperidol; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Prospective Studies
PubMed: 1554179
DOI: 10.1016/s0196-0644(05)82660-5 -
Anesthesia and Analgesia Mar 2003We investigated the effect of IV droperidol on the bispectral index (BIS) in conscious and propofol-sedated patients during spinal anesthesia. Thirty minutes after the... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
UNLABELLED
We investigated the effect of IV droperidol on the bispectral index (BIS) in conscious and propofol-sedated patients during spinal anesthesia. Thirty minutes after the induction of spinal anesthesia, 20 patients were given 2 mg of droperidol IV without administration of other sedatives (conscious group). Another group of patients were sedated with a propofol infusion to maintain BIS at 60 +/- 5 and were administered IV saline (placebo group; n = 20), droperidol 1 mg (dro-1 group; n = 20), or droperidol 2 mg (dro-2 group; n = 20) in a randomized order and in a double-blinded fashion. Although BIS remained the same in the conscious and placebo groups, it significantly decreased after administration of droperidol in the dro-1 and dro-2 groups. The decrease in BIS was significantly larger in the dro-2 group than in the dro-1 group. These results suggest that an antiemetic dose of droperidol enhances the hypnotic effect of propofol in a dose-dependent manner during spinal anesthesia.
IMPLICATIONS
An antiemetic dose of IV droperidol causes a decrease in the bispectral index in patients sedated with propofol during spinal anesthesia. We conclude that droperidol may enhance the hypnotic effect of propofol.
Topics: Adult; Anesthesia Recovery Period; Anesthesia, Spinal; Antipsychotic Agents; Blood Pressure; Conscious Sedation; Double-Blind Method; Droperidol; Electroencephalography; Female; Gynecologic Surgical Procedures; Heart Rate; Humans; Hypnotics and Sedatives; Middle Aged; Propofol
PubMed: 12598260
DOI: 10.1213/01.ANE.0000048517.98692.53 -
Anaesthesia Mar 1980The cardiovascular responses to anaesthesia, laryngoscopy and tracheal intubation were studied in 20 healthy adult patients. The mean arterial pressure increase... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
The cardiovascular responses to anaesthesia, laryngoscopy and tracheal intubation were studied in 20 healthy adult patients. The mean arterial pressure increase following intubation was 1.60 mmHg (SEM +/- 3.52 mmHg) in patients to whom droperidol 150 microgram/kg was given intravenously before anaesthesia compared with a rise of 26.50 mmHg (SEM +/- 4.35 mmHg) in a control group of patients.
Topics: Adult; Anesthesia, Intravenous; Blood Pressure; Droperidol; Heart Rate; Humans; Intubation, Intratracheal; Laryngoscopy; Pulse; Time Factors
PubMed: 7396141
DOI: 10.1111/j.1365-2044.1980.tb05099.x -
Journal of Clinical Anesthesia Jun 2005To determine if droperidol has a morphine-sparing effect when coadministered with morphine via patient-controlled analgesia (PCA) for postoperative pain management. (Clinical Trial)
Clinical Trial Randomized Controlled Trial
STUDY OBJECTIVE
To determine if droperidol has a morphine-sparing effect when coadministered with morphine via patient-controlled analgesia (PCA) for postoperative pain management.
DESIGN
A randomized, double-blind clinical study.
SETTING
Department of Anesthesiology, Kaohsiung Veterans General Hospital, Taiwan.
PATIENTS
One hundred seventy-nine American Society of Anesthesiologists physical status 1 and 2 female patients undergoing abdominal hysterectomy.
INTERVENTIONS
At the end of surgery, patients in the droperidol group received PCA, with the device programmed to deliver a bolus dose of 1 mg morphine and 50 mug droperidol on demand. Patients in the control group received 1 mg morphine on demand. For both groups, PCA lockout was 5 minutes between boluses, with a 4-hour morphine limit of 30 mg.
MEASUREMENTS AND MAIN RESULTS
Pain intensity at rest or on movement and relative sedation score were evaluated and recorded at 6, 12, 24, 48, and 72 hours after surgery. Related side effects were also evaluated and recorded on postoperative days 1, 2, and 3. Morphine use was significantly lower for the droperidol group than the control group during the postoperative 72-hour period (33.9 +/- 9.8 and 54.9 +/- 12.1 mg, respectively), with significantly decreased pain intensity levels for the former relative to the latter at 48 hours (pain intensity on movement: 3.9 +/- 1.2 vs 4.3 +/- 0.9, respectively; P = .049) and 72 hours (pain intensity on movement: 3.0 +/- 1.1 vs 3.6 +/- 0.5, respectively; P = .003; pain intensity at rest: 1.3 +/- 1.0 vs 1.6 +/- 0.7, respectively; P = .033) subsequent to surgery. Control subjects demonstrated a greater frequency of postoperative nausea and vomiting than did their droperidol counterparts on postoperative day 1.
CONCLUSION
Coadministration of 50 mug droperidol and 1 mg morphine on demand via PCA provides a morphine-sparing effect and reduces the frequency of postoperative nausea and vomiting.
Topics: Adult; Analgesia, Patient-Controlled; Double-Blind Method; Droperidol; Drug Therapy, Combination; Female; Humans; Middle Aged; Morphine; Pain, Postoperative; Postoperative Nausea and Vomiting
PubMed: 15950851
DOI: 10.1016/j.jclinane.2004.08.010 -
Neurology Dec 2003
Topics: Acute Disease; Adult; Age of Onset; Akathisia, Drug-Induced; Chronic Disease; Diagnosis, Differential; Dopamine Antagonists; Droperidol; Female; Humans; Male; Mass Screening; Middle Aged; Migraine Disorders; Restless Legs Syndrome
PubMed: 14694067
DOI: 10.1212/01.wnl.0000100667.10887.56